Results 1 to 10 of about 1,394,911 (165)
Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia [PDF]
Research Results in Pharmacology, 2023 Introduction: Thrombopoietin receptor agonists are commonly second-line drugs in immune thrombocytopenia (ITP) pharmacotherapy in children and prescribed for chronic ITP refractory to first-line therapy.
Olga S. Levchenkova +4 more
doaj +2 more sources
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
Therapeutic Advances in Hematology, 2019 The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors commonly used to treat immune thrombocytopenia (ITP). There are three agents that have been investigated for the treatment of chronic ITP: the peptide agent romiplostim
Hanny Al-Samkari, David J. Kuter
doaj +2 more sources
Platelets, 2020 Immune thrombocytopenia (ITP) patients have thrombocytopenia and increased bleeding risk, but, conversely, they also have increased thrombotic risk which appears to be exacerbated by thrombopoietin-receptor agonist (TPO-RA)-treatment. Microvesicles (MVs)
Lamya Garabet +6 more
doaj +2 more sources
Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure [PDF]
Exploration of Drug Science, 2023 Thrombocytopenia is one of the most frequent implications of liver cirrhosis. This condition, when present in the severe form [platelet count (PLT) less than 50 × 109/L] correlates, with an increased risk of bleeding during the main diagnostic ...
Davide Scalabrini +4 more
doaj +1 more source
Cancer Pathogenesis and Therapy, 2023 Immune thrombocytopenia (ITP) is common in the elderly. Because of the coexistence of multiple diseases, there are many reservations regarding corticosteroid use in the elderly. Thrombopoietin (TPO) and its analogs can promote platelet production, but it
Jundong Zhang +3 more
doaj +1 more source
Primary immune thrombocytopenia in children
Pediatria Polska, 2021 Primary immune thrombocytopenia (ITP) is usually a benign and self-limiting disease in children. Due to the complex pathogenesis involving different immunological processes, its course may be unpredictable.
Agnieszka Książek, Tomasz Szczepański
doaj +1 more source
Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism
Clinical Pathology, 2022 Thrombopoietin (TPO)-receptor agonists have heralded a paradigm shift in the treatment of refractory immune thrombocytopenia (ITP). Reactive thrombocytosis has been described as a secondary effect of such therapies.
Rithin Nedumannil +2 more
doaj +1 more source
Haematologica, 2014 Thrombopoietin-receptor agonists increase platelet counts by stimulating the thrombopoietin receptor. Bone marrow fibrosis has been reported in patients receiving thrombopoietin-receptor agonists.
Waleed Ghanima +6 more
doaj +1 more source
Thrombopoietin receptor agonists: ten years later
Haematologica, 2019 The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then, their use has progressively increased around the world; they are currently ...
Waleed Ghanima +4 more
doaj +1 more source
Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain [PDF]
Farmacia Hospitalaria, 2020 Objective: Splenectomy, thrombopoietin receptor agonists and rituximab are the second-line treatments for steroid-resistant adult primary immune thrombocytopenia.
Eduardo Anguita +2 more
doaj +1 more source